Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Other Non Operating Income (2021 - 2024)

Immuneering has reported Other Non Operating Income over the past 4 years, most recently at $91430.0 for Q4 2024.

  • Quarterly results put Other Non Operating Income at $91430.0 for Q4 2024, down 80.31% from a year ago — trailing twelve months through Dec 2024 was $441494.0 (down 66.91% YoY), and the annual figure for FY2025 was $311665.0, down 29.41%.
  • Other Non Operating Income for Q4 2024 was $91430.0 at Immuneering, down from $129310.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for IMRX hit a ceiling of $475595.0 in Q3 2023 and a floor of -$118974.0 in Q4 2021.
  • Median Other Non Operating Income over the past 4 years was $125072.5 (2022), compared with a mean of $133253.0.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 1593.82% in 2022 and later plummeted 94.86% in 2024.
  • Immuneering's Other Non Operating Income stood at -$118974.0 in 2021, then soared by 287.67% to $223278.0 in 2022, then soared by 107.97% to $464352.0 in 2023, then crashed by 80.31% to $91430.0 in 2024.
  • The last three reported values for Other Non Operating Income were $91430.0 (Q4 2024), $129310.0 (Q3 2024), and $7717.0 (Q2 2024) per Business Quant data.